Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
October 2020
-
Press release
Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)
Huntington’s disease is a rare, inherited neurodegenerative disease that leads to progressive disability and deathThere are no approved disease modifying therapies that delay disease onset or slow… -
Ad hoc release
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9… -
Press release
Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)
The European Medicines Agency has granted iptacopan a priority medicines (PRIME) designation in C3 glomerulopathy (C3G). PRIME is granted for medicines that may offer major therapeutic advance… -
Featured News
World Sight Day 2020
Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness. -
Story Access to Healthcare
Meet a visionary who beat the odds to realize his vision of inclusive eye care
Dr. Theophile Tuyisabe is one of only 18 ophthalmologists in Rwanda. We spoke with him about how he does it.
-
Press release
New Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid… -
Press release
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement
Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6…
September 2020
-
Featured News
Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique
Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines. -
Featured News
World Heart Day 2020: From our heart to yours
September 29 is World Heart Day. For the past six decades, Novartis has been working to advance heart health around the world. -
Story Access to Healthcare
Chagas disease: Breaking the silence
Explaining Chagas disease through the stories of patients in Latin America.
-
Ad hoc release
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel,… -
Story Patient Perspectives
Speaking Up in CML
Lisa, a patient living with CML, shares her experience and discusses the importance of speaking up about unmet needs in your disease.